Barclays Raises GE HealthCare (GEHC) PT to $87 Following Q4 Beat, Strong 2026 Outlook

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best IPO stocks to buy right now. On February 6, Barclays increased its price target for GE HealthCare to $87 from $86 and maintained an Equal Weight rating. The firm noted that the company achieved a solid beat in its Q4 2025 results and established a 2026 outlook that exceeds Street expectations.

A day before that, Stifel analyst Rick Wise increased the firm’s price target for GE HealthCare to $98 from $95 with a Buy rating. Following the company’s earnings call, the firm expressed encouragement regarding the prudent outlook provided for 2026.

On February 4, Morgan Stanley raised its price target for GE HealthCare Technologies Inc. (NASDAQ:GEHC) to $85 from $80 with an Equal Weight rating. The firm updated its risk-reward assessment for the stock following Q4 2025 results that surpassed expectations. The firm noted that demand remains robust, supported by a strong order backlog, positive peer performance, and results from the firm’s hospital capital expenditure survey.

GE HealthCare Technologies Inc. (NASDAQ:GEHC) develops, manufactures, and markets products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the US, Canada, and internationally.

While we acknowledge the potential of GEHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.